ArticleBMC public health2026
Prevalence and associated factors of liver fibrosis and steatosis in Gansu, China: a community-based cross-sectional study.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe epidemiology of chronic liver disease in China is undergoing a major transition, shifting from a predominance of viral hepatitis to metabolic-associated liver disease. However, population-based data from Northwest China remain limited. This study aimed to assess the prevalence and independent associated factors of liver fibrosis and steatosis in the general population of Gansu Province, China.
methodsWe conducted a community-based cross-sectional study across three regions in Gansu Province (Huining, Jingtai, and Jingyuan), enrolling 5,043 eligible participants between January and December 2025. All participants underwent anthropometric measurements, laboratory testing, and transient elastography (TE), and completed a structured questionnaire. Liver fibrosis and steatosis were assessed using the liver stiffness measurement (LSM) and ultrasound attenuation parameter (UAP), respectively. Fibrosis was staged as F0 (LSM < 7.3 kPa), F1 (7.3 ≤ LSM < 7.85), F2 (7.85 ≤ LSM < 10.0 kPa), and F3-4 (LSM ≥ 10.0 kPa). Steatosis grades S1 (mild), S2 (moderate), and S3 (severe) were defined using UAP cutoff values of 244, 269, and 296 dB/m, respectively. Independent associated factors were identified using multivariate logistic regression analysis.
resultsAmong 5,043 participants (median age 46 years; 59.8% female), significant fibrosis (≥ F2) was observed in 5.18% (95% CI: 4.56-5.79), and advanced fibrosis or cirrhosis (F3-4) in 1.67% (95% CI: 1.31-2.02). The prevalence of liver steatosis (≥ S1) was 50.45% (95% CI: 49.07-51.85), including 26.87% with moderate-to-severe steatosis (≥ S2) and 7.16% with severe steatosis (S3). Multivariate analysis identified HBV infection (OR 3.19, 95% CI: 1.72-5.92), obesity (OR 5.14, 95% CI: 4.14-8.42), diabetes (OR 3.55, 95% CI: 2.02-6.25), elevated ALT (OR 3.86, 95% CI: 2.96-7.60), and decreased PLT (OR 6.45, 95% CI: 2.03-20.52) as independent factors cross-sectionally associated with advanced fibrosis. Severe steatosis was independently associated with obesity (OR 17.62, 95% CI: 13.50-23.01), diabetes (OR 1.73, 95% CI: 1.17-2.55), hypertension (OR 1.50, 95% CI: 1.14-1.96), dyslipidemia (OR 1.36, 95% CI: 1.04-1.78), decreased PLT (OR 4.16, 95% CI: 1.46-11.84), elevated ALT (OR 2.17, 95% CI: 1.46-3.22) and male sex (OR 1.70, 95% CI: 1.18-2.46).
conclusionsHepatic steatosis was prevalent in this community population of Gansu Province, whereas clinically significant or advanced liver fibrosis remained relatively modest and was predominantly concentrated within high-risk metabolic and viral subgroups. These findings highlight the urgent need for integrated metabolic and viral screening strategies to enable early identification and prevention of progression to advanced liver disease in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.